Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER 5: Oral Semaglutide in T2D with Moderate Renal Impairment
NCT02827708Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2016
- Primary completion
- Apr 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Change in HbA1c at 26 weeks. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02827708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827708.